NASDAQ:OMER
Omeros Corporation Stock News
$3.36
+0.0400 (+1.20%)
At Close: May 31, 2024
Omeros : Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes | MarketScreener
08:13pm, Monday, 10'th Aug 2020Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
08:12pm, Monday, 10'th Aug 2020
Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced that it has commenced concurrent underwritten public offerings of $125,000,000 of shares of its common stock (the "Shares") and $200,000,00
Omeros Corporation Reports Second Quarter 2020 Financial Results
08:01pm, Monday, 10'th Aug 2020
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as wel
Dow Jones Leads, Nasdaq Lags As Market Weighs Trump Orders, China Tensions
04:25pm, Monday, 10'th Aug 2020
The Dow Jones Industrial Average hit new session highs midday while the Nasdaq lagged, amid heightened U.S.-China tensions.
Omeros Rallies On COVID-19 Study Results: What You Should Know
03:41pm, Monday, 10'th Aug 2020
Omeros Corporation (NASDAQ: OMER) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lead investigational human monoclonal antibody.What Ha
ROCE Insights For Omeros
03:35pm, Monday, 10'th Aug 2020
Omeros (NASDAQ: OMER) reported Q1 sales of $23.54 million. Earnings fell to a loss of $23.68 million, resulting in a 0.12% decrease from last quarter. Omeros collected $33.42 million in revenue during
Omeros Reports Coronavirus Treatment Success; Stock Soars
01:01pm, Monday, 10'th Aug 2020
Small Omeros on Monday reported success with a test of its corononavirus treatment, saying it helped the recovery of six patients severely ill with Covid-19.
Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monoclonal antibody targeting mannan-binding lectin-as
Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros’ investigational human monocl
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
04:30pm, Thursday, 06'th Aug 2020
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could This Obscure Biotech Stock Make You a Fortune?
10:27am, Sunday, 26'th Jul 2020
Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
The Play On Omeros
03:48pm, Friday, 17'th Jul 2020
Today, we revisit Omeros. The company has two potential catalysts on the near term horizon and the stock is a good covered call candidate.
Omeros'(NASDAQ:OMER) Share Price Is Down 35% Over The Past Three Years.
07:06pm, Wednesday, 15'th Jul 2020
Many investors define successful investing as beating the market average over the long term. But its virtually certain...
Hedge Funds Are Buying Omeros Corporation (OMER)
08:27pm, Wednesday, 24'th Jun 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
ROCKVILLE, MD / ACCESSWIRE / June 22, 2020 / The American Kidney Fund (AKF) today announced a new corporate membership program open to institutional partners that support AKF's core mission of fi
